Bharat Biotech on Wednesday said that the full data of phase III trials for Covaxin will be made public in July, ANI reported.
The data will be first submitted to the Central Drugs Standard Control Organisation, followed by peer-reviewed journals with a timeline of three months for publication.
Bharat Biotech told ANI once the final analysis of the phase III data is available, it would apply for a full licensure for Covaxin.
The Hyderabad-based firm had earlier said that Covaxin has demonstrated overall interim clinical efficacy of 78 per cent, and 100 per cent efficacy against severe Covid-19 disease in phase III trials.
The interim analysis was based on more than 87 symptomatic cases of Covid-19.